BIODOL THERAPEUTICS
Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (Cyril Rivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.
BIODOL THERAPEUTICS
Social Links:
Industry:
Therapeutics
Founded:
2015-01-01
Address:
Clapiers, Languedoc-Roussillon, France
Country:
France
Website Url:
http://www.biodol.eu
Total Employee:
1+
Status:
Active
Total Funding:
4.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Font Awesome Apache Euro OVH OVH DNS OVH Mail
Similar Organizations
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Advisors List
Current Employees Featured
Founder
Investors List
V-Bio Ventures
V-Bio Ventures investment in Series A - Biodol Therapeutics
Official Site Inspections
http://www.biodol.eu
- Host name: cluster011.ovh.net
- IP address: 213.186.33.40
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Biodol Therapeutics"
Biodol Therapeutics
BIODOL Therapeutics will be attending BIO 2023, Boston, USA, June 3-8. Contact us via a meeting request on the One-on-One partnering platform! 6 April 2023 BIODOL Therapeutics …See details»
Biodol Therapeutics - Crunchbase Company Profile
Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the …See details»
Biodol Therapeutics Company Profile 2024: Valuation, Funding ...
Biodol Therapeutics General Information Description. Operator of a biotech company intended to develop an innovative treatment for chronic pain. The company develops FLT3 inhibitors that …See details»
BIODOL THERAPEUTICS Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for BIODOL THERAPEUTICS of MONTARNAUD, OCCITANIE. Get the latest business insights from Dun …See details»
BIODOL THERAPEUTICS Information - RocketReach
BIODOL Therapeutics is a biotech company developing first-in-class compounds for treating chronic pain. It is based on the discovery by Biodol's scientists of the target FLT3, which is a …See details»
Biodol Therapeutics - Overview, News & Similar companies
Biodol Therapeutics (www.biodol.eu), founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine …See details»
Biodol Therapeutics announces the nomination of its first …
About Biodol Therapeutics Biodol Therapeutics (www.biodol.eu), founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified …See details»
Biodol - VentureRadar
"Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) …See details»
Biodol Therapeutics gathers €7 million to progress its oral,
Biodol Therapeutics (www.biodol.eu), founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine …See details»
Biodol Therapeutics SAS - Drug pipelines, Patents, Clinical trials ...
Www.biodol.eu. Last update 11 Jul 2024See details»
V-Bio Ventures portfolio company Biodol Therapeutics nominates …
Ghent, Belgium, 31 August 2022 – V-Bio Ventures portfolio company Biodol Therapeutics, a French biotech company developing next-generation neuropathic pain treatments, announces …See details»
Biodol Therapeutics Company Profile - Office Locations ... - Craft
Biodol Therapeutics is a biotech company that provides compounds for treating chronic pain. Its technology platform is based on the use of receptor tyrosine kinase (RTK) FLT3 to develop …See details»
Funding Round - Biodol Therapeutics - 2024-05-21 - Crunchbase
May 21, 2024 Organization Name . Biodol Therapeutics . Announced Date May 21, 2024; Funding Type Funding Round; Money Raised . obfuscated. obfuscated. Lead Investors. ...See details»
BIODOL THERAPEUTICS - Pharmaceuticals - Apollo.io
BIODOL Therapeutics is a biotech company developing first-in-class compounds for treating chronic pain. It is based on the discovery by Biodol's scientists of the target FLT3, which is a …See details»
Biodol Therapeutics (company) - Nordic 9
Biodol.eu . See something wrong or missing? Let us know. Offices: Montpellier. Industry: Biotech Health services Pharma. Business model: B2B. Biodol Therapeutics is a biotech startup in …See details»
Biodol Therapeutics receives EUR 4.5 million to progress its
Aug 31, 2020 Biodol Therapeutics (www.biodol.eu), founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the …See details»
A novel approach to neurology could bring relief to people in pain
Aug 31, 2020 This month, V-Bio Ventures announced their investment in Biodol Therapeutics, a French start-up looking to make a difference to people suffering from chronic pain. The …See details»
Biodol Therapeutics from France raises €7M to advance Chronic …
May 27, 2024 Biodol Therapeutics focuses on creating allosteric inhibitors of the FLT3 receptor, co-owning a portfolio of patents with prestigious French research institutions such as the …See details»
Biodol: Uses, Dosage, Side Effects, FAQ - MedicinesFAQ
Sep 19, 2023 Biodol is an orally administered fixed-dose combination of the atypical opioid tramadol and paracetamol, which is indicated in the EU for the symptomatic treatment of …See details»
Research programme: fms-like tyrosine kinase 3 inhibitors - Biodol ...
If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to …See details»